Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.61 |
| ▸ | LAP3 | P28838 | 1/20 | 0.61 |
| ▸ | MMP9 | P14780 | 1/20 | 0.60 |
| ▸ | MMP8 | P22894 | 1/20 | 0.60 |
| ▸ | PPARG | P37231 | 9/20 | 0.58 |
| ▸ | MME | P08473 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | CPA1 | P15085 | 1/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16116809 | 0.92 | GAA (0.58) | LTA4HLAP3MMP9MMP8PPARG | |
| SCHEMBL3499757 | 0.92 | LTA4H (0.65) | LTA4HLAP3MMP9MMP8PPARG | |
| SCHEMBL3499760 | 0.92 | LTA4H (0.65) | LTA4HLAP3MMP9MMP8PPARG | |
| Hydrochloric Acid SCHEMBL29693844 | 0.91 | LTA4H (0.64) | LTA4HLAP3MMP9MMP8PPARG | |
| SCHEMBL13108402 | 0.90 | TACR1 (0.58) | ACE | |
| SCHEMBL2059140 | 0.90 | TACR1 (0.58) | ACE | |
| SCHEMBL12379283 | 0.90 | LTA4H (0.62) | LTA4HLAP3MMP9MMP8PPARG | |
| SCHEMBL16063577 | 0.89 | ATM (0.53) | LTA4HPPARGPPARA | |
| SCHEMBL2035189 | 0.89 | PPARG (0.67) | LTA4HMMP9MMP8PPARGMME | |
| SCHEMBL8760872 | 0.89 | PPARG (0.67) | LTA4HMMP9MMP8PPARGMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| WO-2021202600-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | HAVCR2, CD44, ENGASE | LTA4H 488/4885LAP3 1122/4885MMP9 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.